TinyGems Archives - InvestorWire (IW)

Thursday Nov 16, 2023 - 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) CEO Underscores Commitment to Continued Growth in Letter to Shareholders

Fr8Tech CEO recently wrote a letter to shareholders summarizing the company’s financial milestones and operational successes CEO Javier Selgas discussed the company’s robust revenue growth in Q2 2023 as well as the 93% year-over-year increase in its gross margins during the first half of the year The company’s commitment to innovation has led to the launch of an LTL offering and the establishment of an…

Tuesday Nov 14, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for potential diabetes and weight loss treatment The company hopes to make these drugs more effective with reduced side effects, and even more accessible to people living with diabetes The move is aimed to help the company partner with the behemoths…

Thursday Oct 19, 2023 - 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations

Lexaria, a global innovator in drug delivery platforms, recently announced that it had entered into a securities purchase agreement with a single health-focused institutional investor The agreement is for the purchase of 1,618,330 shares of common stock at $0.97 per share, with gross proceeds amounting to approximately $1.6 million The raised funds will be integral to Lexaria advancing its operations, inching it closer to FDA…

Monday Oct 09, 2023 - 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Announces Strong Financial Results for Second Quarter of 2023

Fr8Tech demonstrated steady growth in Q2 2023 reporting a 29% increase in revenue and a 93% rise in margin compared to 2022 reporting The company projects that it will hit revenues up to $42 million in 2023 – an increase over the previous year at approximately $27 million Fr8Tech offers technology solutions that include a freight matching platform for OTR shipping internationally, a dedicated truck…

Friday Sep 29, 2023 - 10:30 am

GEMXX Corp. (GEMZ) Plans 300% YoY Expansion in Gemstone and Jewelry Production to Meet Growing Demand

GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially GEMXX plans to expand gemstone and jewelry…

Friday Sep 29, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets…

Thursday Sep 28, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a…

Monday Sep 25, 2023 - 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50…

Wednesday Sep 20, 2023 - 11:15 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers GEDI Cube…

Friday Sep 15, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1%…

Tuesday Sep 12, 2023 - 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R) Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands Lexaria has…

Monday Sep 11, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to…

Tuesday Sep 05, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced…

Friday Sep 01, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year 95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated Lexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting…

Wednesday Aug 30, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”) The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”) The orphan drug designation…

Wednesday Aug 30, 2023 - 9:00 am

GEMXX Corp.’s (GEMZ) Strategic Investments Pay Off, as Company Positions itself as a World Class Producer and Distributor of Gemstones and Jewelry

GEMXX recently announced that new investments had strengthened its financial position and would allow it to attract further investment over the next 12 months The announcement followed the acquisition of a 50% ownership stake in Crazy Horse Mining Inc., whose assets include a 100% interest in the Snow Creek and Rosella Creek gold projects in British Columbia Initial production results on the Snow Creek site…

Monday Aug 28, 2023 - 9:00 am

Jewelry Maker GEMXX Corp. (GEMZ) Ramps Up Production at Canadian Gold Site

GEMXX Corporation is a unique vertically integrated jewelry producer, focused on managing costs in-house by mining its own gold and gemstones via its Canadian mine resources for its many jewelry products GEMXX has been engaged this year in bringing one of its British Columbia gold ore sites up to full production The company recently announced the encouraging results of gold ore processed from surface materials…

Wednesday Aug 23, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan…

Tuesday Aug 15, 2023 - 9:45 am

GEMXX Corp. (GEMZ) Expanding Brand Awareness As It Strengthens Mine Project Financing

GEMXX Corporation, a U.S. corporation with mines in Canada, is a mine-to-jewelry production innovator, drawing on its mining assets for the gold and gems it uses in colorful jewelry GEMXX recently engaged the marketing and brand expertise of Hybrid Financial Ltd. as the company seeks to expand awareness of its novel operations in gold and rare gem Ammolite GEMXX similarly is working with InvestorBrandNetwork (“IBN”)…

Thursday Aug 10, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Intent for Human Clinical Study for Diabetes and Weight Loss Following Positive DehydraTECH(TM)-CBD Results in Animals

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with…

Tuesday Aug 08, 2023 - 9:45 am

GEMXX Corp. (GEMZ) Announces Significant Progress Regarding Financing for Gold and Ammolite Mining Operations

The company offers an approach that gives them a cost-saving edge over other producers in the market Preliminary discussions have been made to shortlist engineering firms capable of conducting the necessary SK-1300 technical reports for the company’s newest gold and Ammolite assets – with anticipated completion by the end of FY-2023 GEMXX is participating in Regulation A financing, and interested investors, shareholders, institutions, and financiers,…

Tuesday Aug 08, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates ‘Strategically Important’ New Patent Granted in the US

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine” The company described the new patent as “strategically important” The patent positions the company to tap into the growing oral nicotine market and offers protection in one of the world’s leading oral nicotine markets This patent…

Friday Aug 04, 2023 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Incorporates New Subsidiary, Lexaria Nutraceutical Corp., for Non-Pharmaceutical, Non-Nicotine, and Non-Cannabis DehydraTECH(TM) Formulations

Lexaria Nutraceutical Corp. will keep Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets, excluding pharmaceutical, nicotine, and cannabis molecules Lexaria Pharmaceutical Corp.’s licensing was amended so as to solely focus on pharmaceutical formulations excluding nicotine Lexaria announced in early May that its nicotine trial, NIC-H22-1, had completed dosing with results expected in the near future NIC-H22-1 is anticipated to intercede…

Thursday Aug 03, 2023 - 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Joins AMACARGA, Expanding Footprint, Capabilities, and Industry Presence

Fr8Tech just announced its move to join AMACARGA to expand its capabilities to cater to the growing demands of its clients importing goods from Asia The company’s association with AMACARGA affords it exceptional expertise and adherence to industry standards, bolstering its reputation in the industry The move further compounds Fr8Tech’s aggressive partnerships and collaborations plan, having recently announced its association with Trucker Tools, an automated…

Friday Jul 28, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for…

Friday Jul 21, 2023 - 9:00 am

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it…

Friday Jun 30, 2023 - 2:40 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection…

Friday Jun 30, 2023 - 11:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Announces a Significant Development for Platform Users –Samsara Integration

FRGT just announced its new integration with Samsara, the pioneer of Connected Operations(TM) Cloud The move is seen as a “gamechanger,” with Fr8App customers now able to view and leverage insights from Samsara’s vehicle telematics solution Fr8App’s management is confident that by connecting with industry leaders like Samsara, the company will continue to pave the way for streamlined logistics processes and improved visibility for customers…

Articles

Articles Category: TinyGems